Drug intelligence / Profile preview

methotrexate + bortezomib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of methotrexate, a folate derivative that inhibits enzymes responsible for nucleotide synthesis, and bortezomib, a proteasome inhibitor that prevents the breakdown of proteins important for cell cycle control. This combination is used primarily in the treatment of mantle cell lymphoma, often as part of more comprehensive regimens that may include rituximab and other chemotherapeutic agents.

Targets

DHFR (Dihydrofolate reductase)PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on methotrexate + bortezomib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + bortezomib.

Explore the full profile